RT Plus EGFR-TKI for Wild-type NSCLC

Inclusion Criteria: 1. NSCLC confirmed by histopathology or cytology; 2. Stage IIA - IV NSCLC ,unresectable and could not tolerate chemoradiotherapy; 3. Has measurable lesion \[according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, must have at least one evaluable lesion with the longest dimension \>= 10mm; if the evaluable lesion is lymph node, the shortest dimension should be measured and \>=15mm\]; 4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1; 5. Expectancy life \>= 3 months; Exclusion Criteria: 1. Had systemic anit-NSCLC treatments; 2. Had be treated by HER-targeting agents; 3. Had local radiotherapy for NSCLC; 4. Has upper gastrointestinal physiological disorders, or malabsorption syndrome, or intolerance of oral medication, or active peptic ulcer; 5. Diagnosed other malignant tumor besides NSCLC within 5 years prior the study treatment (except having simple surgical resection with 5-year disease free survival, cured in situ of cervical carcinoma, cured basal cell carcinoma and bladder epithelial tumor); 6. Any evidence to indicate moderate or severe chronic obstructive pulmonary disease (COPD); 7. Known hypersensitivity to EGFR-TKI agents or relevant components in the formulation; 8. Uncontrolled eye inflammation or infection, or any potential circumstances lead to eye inflammation or infection; 9. Pregnancy or breast-feeding women; 10. Ingredients mixed with small cell lung cancer patients; 11. Evidence of any other disease, neurological or metabolic dysfunction, physical examination or laboratory finding giving reasonable suspicion of a disease or condition that contraindicated the use of an investigational drug or puts the subject at high risk for treatment-related complications.